Treatment of Oligometastatic Disease
Mary-Ellen Taplin, MD, discusses the evolving treatment landscape for oligometastatic prostate cancer.
Read More
Mary-Ellen Taplin, MD
Mary-Ellen Taplin, MD, is a Professor of Medicine at Harvard Medical School, Dana-Farber Cancer Institute in Boston, Massachusetts. Dr. Taplin earned her MD from the University of Massachusetts, Worcester. She completed Internal Medicine residency and chief residency at the University of Massachusetts Medical Center and Hematology-Oncology fellowship at Beth Israel Hospital and Harvard Medical School. Before joining the Dana-Farber Cancer Institute, Dr. Taplin served as an Assistant and then Associate Professor of Medicine at the University of Massachusetts for ten years.
Dr. Taplin’s background includes comprehensive training in clinical practice, clinical trials, and correlative tumor analyses. As an academic Genitourinary Oncologist, her research interests are concentrated on prostate cancer. She has focused on molecular analyses of androgen receptor (AR) and AR signaling in both localized high-risk and castration resistant prostate cancer (CRPC). Dr. Taplin created a valuable tumor bank of prostate cancer metastasis biopsies at Dana-Farber Cancer Institute (DFCI). She is the DFCI site lead for the Prostate Cancer Clinical Trials Consortium. She co-led the DFCI Stand Up to Cancer (SU2C) prostate cancer dream team that discovered the importance of mutations in DNA repair pathway genes in prostate cancer. Dr. Taplin has been awarded several Prostate Cancer Foundation challenge grants for her work. She is currently the PI of many trials including a phase 3 trial (PROTEUS) evaluating intensity of androgen deprivation therapy in localized high-risk prostate cancer and DFCI site PI of trials evaluating EZH2 inhibitors and novel AR antagonists in metastatic CRPC.
In her role as Chair of the Executive Committee Clinical Research, Dr. Taplin oversees DFCI clinical research operations and mentors DFCI investigators in development of trials that have potential to improve outcomes for cancer patients.
Talks by Mary-Ellen Taplin, MD